For melanoma, the most promising results have been observed with the monoclonal inhibitory antibody DX-2400, which targets MT1-MMP and effectively slows tumor growth and metastasis in multiple in vivo mouse models of breast cancer and melanoma, both as a standalone treatment and in combination with paclitaxel or bevacizumab [387,388]. The gene discussed is MMP14; the disease is melanoma.